Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
-
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
-
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
-
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
-
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
-
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
-
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at Kidney Week 2023
-
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
-
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human